Welcome to GlobalChemMall

ALL CATEGORIES
Categories
Picture of daclatasvir

daclatasvir

Get Latest Price >

FOB Price contact us for price

Origin: China

Cas No: 1009119-64-5

Specification: 99%min

Min order Quantity: 1 /kg

Supply Ability: 50 mt/month

Lead time: 7 days for OEM, 3 days for ready goods

Vendor:

Payment Terms:

Inquiry now

* Send an Inquiry to us

Add to wishlist

* Name your price
* Start order doesn't mean buying now

  • Products Specification
  • Product Description
  • Property

    CAS No.: 1009119-64-5 Formula: C40H50N8O6 Molecular Weight: 738.87500

    Description

    Daclatasvir (USAN, formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daklinza gained its FDA approval on July 24, 2015 in the United States; it is approved for Hepatitis C genotype 3 infections.
    Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.
    Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.
    It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
    There has been significant controversy over the price that Bristol-Myers Squibb has chosen to charge for the drug. As of December 2015 it cost between $50,000 – $84,000 in high-income countries.
    In Bangladesh, Beacon Pharmaceuticals also produced a generic version product of Daclatasvir under the trade name of Daclavir in October 2015. Beacon also introduced a new combination Sofosbuvir/Daclatasvir under the brand name of Darvoni. Beacon got approval in January 2016 from the Directorate General of Drug Administration, Ministry of Health and Family Welfare, People's Republic of Bangladesh.
    A generic version of daclatasvir was approved in India in December 2015 and is currently being sold under brand names NATDAC (produced by Natco Pharma) and MyDacla (produced by Mylan)

    Basic Info

    Chemical Name daclatasvir
    Synonyms

    Daclatasvir;
    Carbamic acid, N,​N'-​[[1,​1'-​biphenyl]​-​4,​4'-​diylbis[1H-​imidazole-​5,​2-​diyl-​(2S)​-​2,​1-​pyrrolidinediyl[(1S)​-​1-​(1-​methylethyl)​-​2-​oxo-​2,​1-​ethanediyl]​]​]​bis-​, C,​C'-​dimethyl ester;
    EBP 883;
    BMS-790052;
    N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester;

    CAS No. 1009119-64-5
    Molecular Formula C40H50N8O6
    Molecular Weight 738.87500
    PSA 174.64000
    LogP 6.87960

    Properties

    Density 1.249

Hot tags: daclatasvir, China, manufacturers, suppliers, factory, wholesale, low price, high quality